Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy.

European journal of clinical pharmacology - 1 Apr 2013

Desaphy Jean-François, Modoni Anna, Lomonaco Mauro, Camerino Diana Conte

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Flecainide
Share to Mutation
Share to Myotonia Congenita
Share to NAV1.4 Voltage-Gated Sodium Channel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Family

Share to Pharmacogenetics

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23052413
DOI: 10.1007/s00228-012-1414-3
PMCID: PMC3621996

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy.PMID 23052413Read ↗

Diagnosis and Management of Myotonic Dystrophy Type 1.Semantic proximity Read ↗

Drug repurposing in skeletal muscle ion channelopathies.Semantic proximity Read ↗

Myotonic Dystrophies Type 1 and 2: A Summary on Current AspectsSemantic proximity Read ↗

Anaesthesia and orphan disease: management of cardiac and perioperative risks in a patient with Emery-Dreifuss muscular dystrophy.Semantic proximity Read ↗

Myotonic dystrophy mouse models: towards rational therapy developmentSemantic proximity Read ↗

Therapeutic strategies for congenital myasthenic syndromes.Semantic proximity Read ↗

First drug to treat spinal muscular atrophy gets FDA approval: Costly injectable shown to stall debilitating muscle-wasting effects of rare genetic disorder.Semantic proximity Read ↗

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 TrialSemantic proximity Read ↗

Myotonic dystrophy reviewed: back to the future?Semantic proximity Read ↗

Spotlight on MuSK Positive Myasthenia Gravis: Clinical Characteristics, Treatment and OutcomesSemantic proximity Read ↗

[Two cases of potassium-aggravated myotonia induced by SCN4A gene variation].Semantic proximity Read ↗

Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular DystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.